Jose Sanz Peña

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.